Atomo Diagnostics Investor Relations Material
Latest events
H2 2024
Atomo Diagnostics
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Atomo Diagnostics Limited
Access all reports
Atomo Diagnostics Limited provides products in the areas of cancer, infectious diseases, and cardiovascular ailments. Its tests include Visca for diagnosing liver cancer and liver fibrosis/cirrhosis; MammaScreen for early breast cancer detection through measurements of plasma proteins (by testing blood); Chlamydia Screen for the screening or confirmation of Chlamydia trachomatis infections; HIV-1Virology Test System for the qualitative detection of antibodies to human immunodeficiency virus type 1 (HIV-1); and AtomoRapid Malaria Test that detects malaria infection in whole blood samples. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.
Key slides for Atomo Diagnostics Limited
H2 2024
Atomo Diagnostics Limited
H2 2024
Atomo Diagnostics Limited
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
AT1
Country
🇦🇺 Australia